T he election and postelection activities of the past year have been interesting to watch. Both Republicans and Democrats want to help the elderly pay for their prescriptions. Democrats want the government to run the drug benefits plan, but Republicans, not surprisingly, want private insurers to control it. However, these positions mask the real issue, which is what drugs will cost and who will set their prices.
During the election, you probably heard former Vice President Gore accuse pharmaceutical manufacturers of price gouging. Earlier, the House had approved a plan, endorsed by drug manufacturers, to give subsidies to insurance companies offering prescription drug coverage. Congress also approved a bill allowing pharmacists to import prescription drugs from countries where they are sold for less than in the US. However, this reimportation legislation was blocked late last year by the Health and Human Services Department, on the grounds that the government could not guarantee that the drugs would be safe or less expensive.
Elevation of the drug price issue to the national political agenda is justified: It's the budget buster. Prescription prices are now the fastest growing piece of our health care bill. Using data from the Pennsylvania Pharmaceutical Assistance Contract for the Elderly (PACE) program, Families USA reviewed data on the prices of the 50 top-selling prescription drugs used by the elderly. They found that from January 1998 to January 1999, this group of drugs increased in price by 6.6%, while the general rate of inflation for the period was 1.6%. Prices of the 50 drugs during that period increased as follows:
• 72% rose at more than two times the rate of inflation • 46% rose at more than three times the rate of inflation • 34% rose at more than four times the rate of inflation Over 5 years, from January 1994 to January 1999, the cost of these 50 top-sellers to the elderly rose at twice the rate of inflation. Among the prices of the 39 drugs that had been on the market for the entire 5-year period: • 92% increased faster than the inflation rate • 72% rose at a rate at least 1.5 times rate of inflation • 49% rose at more than twice the inflation rate • 26% rose at a rate at least three times the inflation rate How is pricing determined? However difficult to answer, this should be the first question asked if an attempt is made to reduce drug prices-especially for the elderly. It is a given that the cost of research and development for new agents is high, and Americans pay more for pharmaceuticals than patients elsewhere in the world. A recent International Trade Commission report has suggested that an examination of international drug pricing differences between the United States and other countries may not be feasible. Differences in sample size, distribution endpoints, transaction prices, and currency conversions make comparison difficult. The US is, however, the only developed country in which the government does not control drug prices.
Here are a few examples:
• France: The French health care system decides which drugs are eligible for reimbursement and sets reimbursement prices. The entire population is covered. An annual ceiling is set between the government and manufacturers; if the ceiling is exceeded, manufacturers cover the shortfall. • Canada: New agents can't be priced higher that their average cost in the US, UK, Switzerland, Germany, Sweden, France, and Italy. Prices can then rise at the rate of inflation. Provinces negotiate further discounts. • Germany: Manufacturers freely set prices. Reimbursement is controlled based on therapeutic benefit within the national health care system. Limits on spending are enforced and all drugs in the same therapeutic class are reimbursed at the same rate. Because the US has no price controls, most of the profit is made here and most of the research is done here. The US, in essence, funds much of global research. Some also believe it is our obligation to pay higher prices to offset those offered to developing countries. Although the system appears flawed, I do not believe a government-run system could support the level of innovation required by this industry. The private system allows more money to be directed to research and development that potentially serve markets and diseases that would otherwise be ignored.
Editorial
President Bush has proposed an "Immediate Helping Hand" drug-benefits program for low-income seniors that, combined with Medicare modernization, would receive $153 billion in budgetary funding over 10 years.
Democrats claim that if Bush's budget passes, there will not be enough money for a Medicare prescription drug benefit this year.
No matter who sets prices for drugs, I do hope that Republicans and Democrats will bridge their ideological gap and effect a resolution soon, so that patients not covered by a drug benefit program do not have to choose between food and prescription medications. !
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